Introduction {#s1}
============

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection ([@B1]), which affects approximately 30 million people worldwide ([@B2]). In the UK, sepsis is the second leading cause of death with 36,000--64,000 patients dying each year ([@B3]) costing the NHS £2.5 billion annually ([@B4]). The development of cardiac dysfunction affects 40% of septic patients ([@B5]) and is associated with an increased mortality rate of 70--90% in comparison to 20% mortality in patients who do not present with cardiac dysfunction ([@B6]). However, the mechanisms that underlie this cardiac dysfunction are not well-known. Evidence suggests that multiple factors contribute to the pathophysiology of the cardiac dysfunction associated with sepsis. These include the activation of NF-κB and NLRP3 leading to excessive formation of e.g., IL-1 and TNF-α ([@B7], [@B8]). There are currently no drugs for the specific treatment of the cardiac dysfunction (or indeed the multiple organ dysfunction) associated with sepsis that specifically target NF-κB and the NLRP3 inflammasome.

Bruton\'s tyrosine kinase (BTK) plays a role in innate immunity and is a critical component in the development of B cells ([@B9]). The FDA has approved the use of the irreversible BTK inhibitors ibrutinib (first generation) in chronic lymphatic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and graft vs. host disease ([@B10]) and acalabrutinib (more selective, second generation) in MCL ([@B11]). Ibrutinib is also approved by the EMA for the treatment of CLL, MCL, and WM ([@B12]), whereas acalabrutinib has received an orphan designation for CCL, MCL, and lymphoplasmacytic lymphoma ([@B13]--[@B15]). During sepsis, bacterial LPS stimulates TLR4 and BTK is directly involved in the activation of this signaling pathway. Specifically, BTK binds to the TIR domain of TLR4 and its adaptor molecules (also found in other TLR\'s) MyD88 and Mal, and results in downstream activation of NF-κB and the generation of proinflammatory cytokines ([@B16]). BTK also regulates the assembly and, hence, activation of the NLRP3 inflammasome by binding to the ASC component ([@B17], [@B18]). Inhibition of BTK by BTK inhibitors reduces NF-κB activation and the formation of NF-κB-dependent cytokines in murine models of arthritis ([@B19]).

Given the importance of TLRs and NLRP3 in the pathophysiology of sepsis, we hypothesized that BTK inhibitors, such as ibrutinib or acalabrutinib, may attenuate the cardiac dysfunction in a murine model of polymicrobial sepsis. Additionally, we set out to investigate the potential effects of BTK inhibition on (a) the activation of NF-κB and NLRP3 in the heart, and (b) the serum levels of key, pro- and anti-inflammatory cytokines and chemokines.

Methods {#s2}
=======

Ethical Statement
-----------------

The Animal Welfare Ethics Review Board of Queen Mary University of London approved all experiments in accordance with the Home Office guidance on the operation of Animals (Scientific Procedure Act, 1986) published by Her Majesty\'s Stationary Office, and the Guide for the Care and Use of Laboratory Animals of the National Research Council. Work was conducted under U.K. home office project license number PC5F29685. All *in vivo* experiments are reported in accordance to ARRIVE guidelines ([@B20]).

Animals
-------

This study was carried out on 40 10-week-old male C57BL/6 mice (Charles River Laboratories UK Ltd., Kent, UK) weighing 25--30 g and kept under standard laboratory conditions. Six mice were housed together (in each cage) with access to a chow diet and water *ad libitum*. They were subjected to a 12-h light and dark cycle with a temperature maintained at 19--23°C.

Drugs
-----

Ibrutinib and acalabrutinib were purchased from Selleck Chemicals. Stock solutions were made in DMSO 5% and cyclodextrin 30% (vehicle).

Murine Model of Polymicrobial Sepsis Caused by Cecum Ligation and Puncture (CLP)
--------------------------------------------------------------------------------

Mice were randomized to undergo either sham operation, CLP + vehicle (5% DMSO + 30% cyclodextrin), CLP + ibrutinib (30 mg/kg), or CLP + acalabrutinib (3 mg/kg). Before surgery, mice were injected with buprenorphine (0.05 mg/kg, i.p.). Mice were initially anesthetized by isoflurane (3 L/min) and oxygen (1 L/min) in an anesthetic chamber and maintained with isoflurane (2 L/min) and oxygen (1 L/min) via a face mask. Temperature was monitored via a rectal probe and kept at 37°C by a homeothermic mat. Veet® hair removal cream was used to remove the fur from the abdomen of the mouse and skin was then cleaned with 70% ethanol. The abdomen was opened with a 1.5 cm midline incision to expose the cecum. The cecum was fully ligated below the ileocecal valve, and a G-18 needle was used to puncture two holes in the top and bottom of the cecum. A small amount of feces was then squeezed out. The cecum was returned to the abdomen in its anatomical position and 5 ml/kg of saline was administered into the abdomen before its closure. Saline (10 ml/kg s.c.) was administered directly after surgery. One hour after CLP, vehicle (5% DMSO + 30% cyclodextrin), ibrutinib (30 mg/kg), or acalabrutinib (3 mg/kg) was administered intravenously. At 6 and 18 h after surgery, antibiotics (imipenem/cilastatin; 20 mg/kg dissolved in saline s.c.) and an analgesic (buprenorphine; 0.05 mg/kg i.p.) were administered. After 24 h, cardiac function was assessed by echocardiography *in vivo*. Mice that underwent sham surgery were not subjected to ligation or perforation of the cecum but were otherwise treated the same way, 1 h after surgery sham animals were treated with vehicle (5% DMSO + 30% cyclodextrin).

Renal Dysfunction Analysis
--------------------------

Renal dysfunction was analyzed in all mice. The mice were anesthetized with isoflurane (3 L/min) and oxygen (1 L/min) before being sacrificed. Cardiac puncture was performed with a G25 needle and non-heparinized syringes to obtain approximately 0.7 ml of blood. The blood was immediately decanted into 1.3 ml serum gel tubes (Sarstedt, Nürnbrecht, Germany). The heart and lungs were then removed. The blood samples were centrifuged for 3 min at 9,000 RPM to separate the serum, where 100 μL of serum was pipetted into an aliquot and snap frozen in liquid nitrogen and stored at −80°C for further analysis. The serum was then sent to an independent veterinary testing laboratory (MRC Harwell Institute, Oxford, UK) to blindly quantify serum urea and creatinine known markers of renal dysfunction.

Echocardiography
----------------

At 24 h after CLP, cardiac function was assessed with a Vevo 3100 imaging system (VisualSonics, Toronto, Ontario, Canada). Mice were fully sedated in an anesthetic chamber with isoflurane (3 L/min) and oxygen (1 L/min) and were then transferred to the thermoregulatory platform in the supine position, where their paws were taped on to the EKG leads. Anesthetic was maintained throughout the entire procedure via a nosecone with isoflurane (0.5--2.0 L/min) and oxygen (1 L/min). The fur on the chest was removed by Veet® hair removal cream and pre-warmed echo gel was placed onto the shaven chest. The heart was then imaged with the MX550D imaging probe. To measure the left ventricle in B-mode the probe was placed along the long axis of the left ventricle, and directed toward the right of the mouse, here we measured percentage fractional area change (FAC%). The probe was then rotated 90° to visualize the short axis in the M-mode where the following parameters were measured: the percentage ejection fraction (EF%) and fractional shortening (FS%).

Western Blot Analysis
---------------------

Immunoblot analyses of cardiac tissue samples were carried out using a semi-quantitative western blotting analysis. The antibody used were: 1:1,000 rabbit anti-Ser^176/180^-IKKα/β, 1:1,000 rabbit anti-total IKKα/β, 1:1,000 mouse anti-Ser^32/36^-IκBα, 1:1,000 mouse anti-total IκBα, 1:1,000 rabbit anti-NF-κB, 1:1,000 rabbit anti-total BTK, 1:1,000 rabbit anti-Tyr^1217^ PLCγ, 1:1,000 rabbit anti-total PLCγ (from Cell Signaling), 1:1,000 rabbit anti-Tyr^223^-BTK, 1:5,000 rabbit anti NLRP3 inflammasome (from Abcam), 1:1,000 mouse anti-caspase 1 (p20) (from Adipogen). The apex of the heart was taken and homogenized in 1:10 of homogenization buffer at 4°C. Nuclear and cytosolic proteins were then extracted as previously described ([@B21]) and concentrations were quantified by bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific Rockford, IL). Proteins were separated by 8% sodium dodecyl sulfate (SDS)-PAGE and transferred to polyvinyldenedifluoride membranes. Membranes were blocked in 10% milk solution with TBS-Tween and then incubated with the primary antibody overnight at 4°C. The next day the secondary antibody was added for 30 min at room temperature and visualized using the ECL detection system. Tubulin and histone 3 were used as loading control. The immunoreactive bands were analyzed by the Bio-Rad Image Lab Software™ 6.0.1 and results were normalized to the sham bands.

Multiplex Flow Immunoassay
--------------------------

The principle of multiplex flow immunoassay technology has been reviewed previously ([@B22], [@B23]). Cytokines, chemokines and a growth factor were determined in serum by Bio-Plex Pro Mouse Chemokine 33-plex panel assay (Bio-Rad, Kabelsketal, Germany). The cytokines IL-1ß,−2,−4,−6,−10,−16, CCL1,−2,−3,−4,−5,−7,−11,−12,−17,−19,−20,−22,−24,−25, −27, IFN-γ, TNF-α and the chemokines CX3CL1, CXCL1,−2,−5,−10,−11,−12,−13,−16 and the growth factor GM-CSF were measured according to the manufacturer\'s instructions. The assays were performed in one batch, with samples randomly distributed. The lower detection limit was 3.2 pg/ml for all the analytes. Data were collected and analyzed using a Bio-Plex® 200 instrument equipped with Bio-Plex Manager software (Bio-Rad).

Statistical Analysis
--------------------

All data in text and figures are expressed as mean ± standard error mean (SEM) of *n* observations. Measurements obtained from the intervention, control and sham were analyzed by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test on GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). Correlations coefficients were determined by Pearson\'s correlation with *P*-values based on two-tailed tests. Differences were considered to be statistically significant when *P* \< 0.05.

Results {#s3}
=======

Ibrutinib or Acalabrutinib Attenuate the Cardiac Dysfunction Caused by CLP-sepsis
---------------------------------------------------------------------------------

When compared to sham-operated animals, mice subjected to CLP for 24 h ([Figure 1A](#F1){ref-type="fig"}) demonstrated a significant reduction in EF, FS, and FAC (*P* \< 0.0001; [Figures 1B--E](#F1){ref-type="fig"}) indicating the development of systolic cardiac dysfunction. The observed reduction in EF also negatively correlated with the rise of the chemokines CXCL10 and CXCL11, both of which are well-known biomarkers of left ventricular dysfunction ([Figures 1F--I](#F1){ref-type="fig"}). When compared to CLP mice treated with vehicle (control), the administration of ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) at 1 h after CLP significantly attenuated the decline in EF, FS and FAC caused by CLP (*P* \< 0.01; [Figures 1B--E](#F1){ref-type="fig"}). The rise in the serum levels of the chemokines CXCL10 and CXCL11 caused by CLP were also significantly reduced by either ibrutinib or acalabrutinib (*P* \< 0.05; [Figures 1F--I](#F1){ref-type="fig"}). No significant differences were observed in any of the cardiac parameters or cytokines measured in CLP animals treated with either ibrutinib or acalabrutinib (*P* \> 0.05; [Figures 1B--I](#F1){ref-type="fig"}). To gain a better insight into the mechanism by which the two BTK-inhibitors reduce the cardiac dysfunction associated with sepsis, we investigated the effects of ibrutinib and acalabrutinib on (a) BTK-activation and signaling, (b) NF-κB activation, and (c) NLRP3 inflammasome assembly and activation (see below).

![Ibrutinib or acalabrutinib attenuate the cardiac dysfunction caused by CLP-sepsis. Mice were randomly assigned to undergo CLP or sham surgery (*n* = 10). One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). Cardiac function was assessed 24 h after CLP surgery (*n* = 10 per group). **(A)** Illustration of the timelines of the CLP model. **(B)** Representative M-mode echocardiograms. **(C)** Ejection fraction (%). **(D)** Fractional shortening (%). **(E)** Fractional area change (%). **(F)** CXCL10 serum concentration (pg/ml). **(G)** CXCL11 serum concentration (pg/ml). **(H)** correlation of ejection fraction and CXCL10 serum concentration. **(I)** Correlation of ejection fraction and CXCL11 serum concentration. All data are expressed as mean ± SEM for *n* number of observations. A value of \*\*\*\**P* \< 0.0001, \*\*\**P* \< 0.001, \*\**P* \< 0.01 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test. Correlations coefficients were determined by Pearson\'s correlation with *P*-values based on two-tailed tests.](fimmu-10-02129-g0001){#F1}

Ibrutinib or Acalabrutinib Attenuate the Renal Dysfunction Caused by CLP-sepsis
-------------------------------------------------------------------------------

Urea and creatinine were measured to study the effect of CLP (in the absence and presence of BTK inhibitors) on kidney function. When compared to sham, mice subjected to CLP and treated with vehicle had a significant increase of urea and creatinine, indicating kidney dysfunction (*P* \< 0.0001; [Figure 2](#F2){ref-type="fig"}). Administration of ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) to CLP mice significantly attenuated the rise in urea and creatinine when compared to CLP mice treated with vehicle (*P* \< 0.01; [Figure 2](#F2){ref-type="fig"}), without any significant difference between the two treatment.

![Ibrutinib or acalabrutinib attenuate the renal dysfunction caused by CLP-sepsis. Mice were randomly assigned to undergo CLP or sham surgery (*n* = 10). One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP, blood samples were collected for analyses (n = 10 per group). **(A)** Serum urea (mmol/L). **(B)** Serum creatinine (μmol/L). All data are expressed as mean ± SEM for *n* number of observations. A value of \*\*\*\**P* \< 0.0001, \*\*\**P* \< 0.001, \*\**P* \< 0.01 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test.](fimmu-10-02129-g0002){#F2}

Cardiac BTK Is Activated in CLP Mice and Reduced by Ibrutinib or Acalabrutinib
------------------------------------------------------------------------------

Using Western blot analysis, we investigated whether CLP-sepsis leads to an activation of BTK in the heart. The activation of BTK and the subsequent activation of BTK-signaling involves (a) phosphorylation of BTK at Tyr^223^ and (b) the phosphorylation of PLCγ at Tyr^1217^ by phosphorylated (activated) BTK as the first step in the BTK-signaling cascade. When compared to sham operated mice, CLP mice treated with vehicle demonstrated significant increases in the phosphorylation of cardiac BTK at Tyr^223^ and the phosphorylation of PLCγ at Tyr^1217^, indicating that BTK is activated in septic hearts (*P* \< 0.0001; [Figure 3A](#F3){ref-type="fig"}). Administration of ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) in CLP mice resulted in a significant decrease in the phosphorylation of cardiac BTK at Tyr^223^ and the phosphorylation of PLCγ at Tyr^1217^ when compared to CLP mice treated with vehicle (*P* \< 0.0001; [Figure 3B](#F3){ref-type="fig"}) demonstrating that the doses of the two BTK inhibitors used in our study caused a significant inhibition of BTK-signaling in the heart. No significant differences were observed in the degree of phosphorylation of cardiac BTK at Tyr^223^ and the phosphorylation of PLCγ at Tyr^1217^ in CLP-animals treated with either ibrutinib or acalabrutinib (*P* \> 0.05; [Figures 3A,B](#F3){ref-type="fig"}).

![Cardiac BTK is activated in CLP mice and reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP surgery, the activation of BTK in the heart was analyzed by western blot analysis (*n* = 5 per group). Specifically, densitometric analysis of the bands is expressed as relative OD of **(A)** phosphorylation of BTK at Tyr^223^ corrected for the corresponding total BTK and normalized using the related sham band. **(B)** Phosphorylation of PLCγ at Tyr^1217^ corrected for the corresponding total PLCγ. All data are expressed as mean ± SEM for *n* number of observations. A value of \*\*\*\**P* \< 0.0001 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test.](fimmu-10-02129-g0003){#F3}

Cardiac NF-κB Activation in CLP Mice Is Reduced by Ibrutinib or Acalabrutinib
-----------------------------------------------------------------------------

To understand the signaling mechanism associated with the observed cardiac dysfunction, we investigated the effect of BTK inhibition on the activation of key signaling pathways of inflammation including pathways leading to the activation of NF-κB. When compared to sham operated mice, CLP mice treated with vehicle had significant increases in the phosphorylation of IKKα/β at Ser^176/180^, the phosphorylation of IκBα at Ser^32/36^ and the translocation of p65 to the nucleus (*P* \< 0.001; [Figures 4A--C](#F4){ref-type="fig"}). When compared with CLP mice treated with vehicle, treatment of CLP mice with ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) significantly attenuated the increases in cardiac phosphorylation of IKKα/β at Ser^176/180^ and IκBα at Ser^32/36^ and the nuclear translocation of p65 (*P* \< 0.0001; [Figures 4A--C](#F4){ref-type="fig"}). No significant differences were observed in the degree of phosphorylation of IKKα/β at Ser^176/180^, the phosphorylation of IκBα at Ser^32/36^ and the translocation of p65 to the nucleus in CLP animals treated with either ibrutinib or acalabrutinib (*P* \> 0.05; [Figures 4A--C](#F4){ref-type="fig"}).

![Cardiac NF-κB activation in CLP mice is reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h cardiac tissue was collected and signaling was assessed (*n* = 5 per group). Densitometric analysis of the bands is expressed as relative OD of **(A)** phosphorylation of IKKα/β at Ser^176/180^ corrected for the corresponding total IKKα/β and normalized using the related sham band. **(B)** Phosphorylation of IκBα at Ser^32/36^ corrected for the corresponding total IκBα and normalized using the related sham band. **(C)** NF-κB p65 in both nucleus and cytosol and expressed as a ratio, normalized using the sham related bands. All data are expressed as mean ± SEM for *n* number of observations. A value of \*\*\*\**P* \< 0.0001 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test.](fimmu-10-02129-g0004){#F4}

Cardiac NLRP3 Activation in CLP Mice Is Reduced by Ibrutinib or Acalabrutinib
-----------------------------------------------------------------------------

We next assessed the potential involvement of NLRP3 in the cardiac dysfunction of CLP mice. When compared to sham operated mice, CLP-sepsis (vehicle-treatment) resulted in the increased expression of the NLRP3 inflammasome and cleavage of pro-caspase-1 to caspase-1 in the heart and a rise in serum IL-1β (*P* \< 0.0001; [Figures 5A--C](#F5){ref-type="fig"}). When compared to CLP mice treated with vehicle, treatment of CLP mice with ibrutinib or acalabrutinib significantly inhibited the expression of NLRP3, cleavage of pro-caspase-1 to caspase-1 and the rise in IL-1β (*P* \< 0.01; [Figures 5A--C](#F5){ref-type="fig"}), without any significant difference between the two drug treatments.

![Cardiac NLRP3 activation in CLP mice is reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP surgery, the assembly and activation of NLRP3 in the heart was analyzed by western blot analysis (*n* = 5 per group). Specifically, densitometric analysis of the bands is expressed as relative OD of **(A)** NLRP3 activation, corrected against tubulin and normalized using the sham related bands. **(B)** Pro-caspase-1 against activated caspase-1 and normalized using the sham related bands. **(C)** IL-1β serum concentration analyzed by multiplex assay (*n* = 8). All data are expressed as mean ± SEM for *n* number of observations. A value of \*\*\*\**P* \< 0.0001, \*\**P* \< 0.01 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test.](fimmu-10-02129-g0005){#F5}

Relationship Between BTK Activation and Cardiac Dysfunction in CLP-sepsis
-------------------------------------------------------------------------

To address the question whether the degree of activation of BTK correlates with alterations in cardiac function, we correlated the degree of phosphorylation of BTK at Tyr^223^ ([Figure 6A](#F6){ref-type="fig"}) and the phosphorylation of PLCγ at Tyr^1217^ ([Figure 6B](#F6){ref-type="fig"}) with EF. We found a highly significant negative correlation between the degree of BTK and PLCγ activation and the decline in EF, strongly suggesting that BTK activation drives or precedes the cardiac dysfunction associated with sepsis. To address the question whether the degree of activation of BTK also correlates with alterations in the activation of NF-κB, we correlated the degree of phosphorylation of BTK at Tyr^223^ with the translocation of p65 ([Figure 6C](#F6){ref-type="fig"}) and the phosphorylation of IKKα/β at Ser^176/180^ ([Figure 6D](#F6){ref-type="fig"}). We found a highly significant positive correlation between the degree of BTK activation and the activation of NF-κB when measured as either the translocation of p65 ([Figure 6C](#F6){ref-type="fig"}) and the phosphorylation of IKKα/β at Ser^176/180^ ([Figure 6D](#F6){ref-type="fig"}). To address the question whether the degree of activation of BTK also correlates with alterations in the assembly and activation of the inflammasome, we correlated the degree of phosphorylation of BTK at Tyr^223^ with either NLRP3 assembly ([Figure 6E](#F6){ref-type="fig"}) or the activation of caspase-1 ([Figure 6F](#F6){ref-type="fig"}). We found a highly significant positive correlation between the degree of BTK activation and the NLRP3 ([Figure 6E](#F6){ref-type="fig"}) increased expression and the activation of caspase-1 ([Figure 6F](#F6){ref-type="fig"}).

![Relationship between BTK activation and cardiac dysfunction in CLP-sepsis. Correlation data to show **(A)** ejection fraction (%) vs. phosphorylation of BTK at Tyr^223^. **(B)** ejection fraction (%) vs. of PLCγ at Tyr^1217^. **(C)** Phosphorylation of BTK at Tyr^223^ vs. NF-κB p65. **(D)** Phosphorylation of BTK at Tyr^223^ vs. phosphorylation of IKKα/β atSer^176/180^. **(E)** Phosphorylation of BTK at Tyr^223^ vs. NLRP3. **(F)** Phosphorylation of BTK at Tyr^223^ vs. activated/pro-caspase-1. Data was analyzed by the Pearson correlation coefficient test to calculate the r value and a two tailed *T*-test for significance.](fimmu-10-02129-g0006){#F6}

Systemic Inflammation in CLP Mice Is Reduced by Ibrutinib or Acalabrutinib
--------------------------------------------------------------------------

We also studied the effect of CLP (in the absence and presence of BTK inhibitors) on the systemic synthesis of pro-inflammatory cytokines, anti-inflammatory cytokines and pro-inflammatory chemokines. When compared to sham operated mice, CLP (vehicle) resulted in a significant rise in the serum levels of (a) the pro-inflammatory cytokines TNF-α, IFN-γ, IL-6; (b) the anti-inflammatory cytokines IL-4 and IL-10, and (c) the pro-inflammatory chemokines KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24 (*P* \< 0.05; [Figures 7A--H](#F7){ref-type="fig"}). The sepsis-induced increase in these cytokines and chemokines was significantly attenuated by both BTK inhibitors, the only exception being IL-6, which was not significantly reduced by ibrutinib but a trend in reduction was observed. No significant differences were observed in the levels of cytokines or chemokines in CLP animals treated with either ibrutinib or acalabrutinib (*P* \> 0.05; [Figures 7A--H](#F7){ref-type="fig"}).

![Systemic inflammation in CLP mice is reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP, blood samples were collected, and the serum concentration of cytokines and chemokines were measured by a multiplex assay (*n* = 8 per group). **(A)** TNF-α serum concentration (pg/ml). **(B)** IL-6 serum concentration (pg/ml). **(C)** IFN-γ serum concentration (pg/ml). **(D)** KC/CXCL1 serum concentration (pg/ml). **(E)** Eotaxin-1/CCL11 serum concentration (pg/ml). **(F)** Eotaxin-2/CCL24 serum concentration (pg/ml). **(G)** IL-10 serum concentration (pg/ml). **(H)** IL-4 serum concentration (pg/ml). All data are expressed as mean ± SEM for *n* number of observations. Correlations coefficients were determined by Pearson\'s correlation with *P*-values based on two-tailed tests a value of \*\*\*\**P* \< 0.0001, \*\*\**P* \< 0.001, \*\**P* \< 0.01, \**P* \< 0.05 was considered to be statistically significant.](fimmu-10-02129-g0007){#F7}

The data of all other cytokines/chemokines/growth factors that we measured in all groups are provided in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}.

Discussion {#s4}
==========

We show here, for the first time, that administration of two structurally different BTK inhibitors (ibrutinib and acalabrutinib) both ameliorate the cardiac dysfunction (measured as decline in EF, FS, or FAC by echocardiography) caused by CLP-sepsis. The observed decline in EF also was associated with a significant increase in the serum levels of two, well-known biomarkers of left ventricular dysfunction, namely CXCL10 and CXCL11 ([@B24]--[@B26]). Most notably, ibrutinib or acalabrutinib also attenuated the rises in CXCL10 and CXCL11 caused by CLP-sepsis. In addition, ibrutinib or acalabrutinib also reduced the renal dysfunction (measured as increase in serum urea or creatinine) caused by CLP-sepsis. Thus, both BTK inhibitors reduced the cardiac and renal dysfunction caused by sepsis.

What, then, is the mechanism by which ibrutinib or acalabrutinib reduce the cardiac (renal) dysfunction caused by sepsis? Ibrutinib is a potent BTK inhibitor, but not very specific (as it also inhibits a multitude of other kinases), which is approved by the FDA and the EMA for the use in CLL, MCL, and WM. Acalabrutinib is a potent, but highly specific BTK inhibitor: At a (relatively high) concentration of 1 μM, acalabrutinib strongly inhibited only the following 5 kinases: BTK, Bmx, ErbB4, RIPK2, and TEC, while the same concentration of ibrutinib inhibited 35 kinases. It should be noted that the doses of acalabrutinib and ibrutinib that we used in our study in the mouse resulted in a similar, \~70%, inhibition of BTK activity in septic hearts. We, therefore, propose that inhibition of BTK activity explains the observed beneficial effects of ibrutinib or acalabrutinib in sepsis. The activation of BTK and the subsequent activation of BTK signaling involves (a) phosphorylation of BTK at Tyr^223^ and (b) the phosphorylation of PLCγ at Tyr^1217^ by phosphorylated (activated) BTK as the first step in the BTK signaling cascade ([@B27]). We report here that sepsis results in significant increases in the phosphorylation of cardiac BTK at Tyr^223^ and the phosphorylation of PLCγ at Tyr^1217^, indicating that BTK is activated in septic hearts. Most notably, the activation of BTK negatively correlated with EF indicating that activation of BTK is associated with the cardiac dysfunction in sepsis. Indeed, inhibition of BTK activity with ibrutinib or acalabrutinib in the heart of septic animals reduces the cardiac dysfunction in sepsis suggesting that activation of BTK plays a pivotal role in the pathophysiology of the cardiac dysfunction in sepsis.

What are the mechanisms by which the activation of BTK (in the heart) leads to cardiac dysfunction in sepsis? There is good evidence that (a) the activation of BTK precedes the activation of NF-κB ([@B16]), and (b) the activation of NF-κB plays an important role in the cardiac dysfunction in sepsis ([@B28], [@B29]). Specifically, inhibition of the activity of NF-κB attenuates the cardiac dysfunction in sepsis ([@B30], [@B31]). We report here, for the first time, that (a) activation of BTK is associated activation of NF-κB in septic hearts, and (b) inhibition of BTK activity with ibrutinib or acalabrutinib reduces both the activation of NF-κB in septic hearts and the cardiac dysfunction caused by sepsis. Thus, we propose that inhibition of the activation of NF-κB contributes to the observed beneficial effects of the BTK inhibitors ibrutinib and acalabrutinib in sepsis. When challenging BTK KO-mice with LPS, Gabhann and colleagues observed reduced (i) activation of NF-κB p65, (ii) Akt phosphorylation, and (iii) M1 polarization of macrophages ([@B32]).

Activation of NF-κB drives the formation of a number of pro- and anti-inflammatory cytokines and chemokines. We report here that CLP-sepsis leads to a significant increase in the serum levels of the pro-inflammatory cytokines TNF-α, IL-6, IFN-γ, anti-inflammatory cytokines IL-10, IL-4 and the chemokines KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24, all of which importantly contribute to the local and systemic inflammation and organ injury associated with sepsis ([@B33]). Most notably, we see the powerful pro-inflammatory cytokine TNF-α to be ameliorated by both BTK inhibitors. TNF-α has been implicated in murine models of sepsis and in humans with sepsis. TNF-α acts in an autocrine and paracrine manner leading to macrophage production and activation, resulting in the release of other proinflammatory cytokines such as IL-6 and IL-8 ([@B34], [@B35]).

Similarly, there is also good evidence that activation of BTK plays a crucial role in the assembly and activation of the NLRP3 inflammasome ([@B17], [@B18]). The activation of the NLRP3 inflammasome has been suggested to play a role in the cardiac dysfunction ([@B36]) and the pathophysiology of sepsis ([@B37]). Others have reported that inhibition of the assembly and activation of NLRP3 inflammasome protects against microbial sepsis ([@B37]). We report here for the first time that (a) activation of BTK is associated with the activation of the NLRP3 inflammasome in septic hearts, and (b) inhibition of BTK activity with ibrutinib and acalabrutinib reduces both the assembly and subsequent activation of the NLRP3 inflammasome in septic hearts (and the cardiac dysfunction caused by sepsis). Thus, we propose that inhibition of the activation of the NLRP3 inflammasome may also contribute to the observed beneficial effects of the BTK inhibitors ibrutinib and acalabrutinib in sepsis.

Activation of the NLRP3 inflammasome drives the formation of IL-1β and IL-18, both of which play an important role in the systemic inflammation and/or organ dysfunction in sepsis ([@B38]). Specifically, inhibition of caspase-1 results in an inhibition of IL-18 and IL-1β secretion, which, in turn, attenuated the cardiac dysfunction caused by myocardial ischemia ([@B39]). The role of the inflammasome in the pathophysiology of sepsis, however, is still controversial: For example, survival was similar in wild-type and caspase-1/11 knockout mice with sepsis, while the neutralization of IL-1 and IL-18 reduced mortality in endotoxemia ([@B38]). Here we show that BTK inhibition results in reduced serum levels of IL-1β, and this was associated with an improvement of cardiac function.

The evaluation of the efficacy of the BTK inhibitors used in our study depends on the assumption that the development of organ dysfunction (and specifically cardiac and renal dysfunction) correlates with outcome. There is good evidence that the occurrence of cardiac and/or renal dysfunction correlates positively with an increase in mortality in patients with sepsis ([@B6]). We have, however, not investigated the effects of BTK inhibition on survival in animals with sepsis due to ethical reasons. It would be useful to confirm whether inhibition of BTK activity does, indeed, improve survival in longer models of sepsis (rather than the very acute model employed here).

In addition to inhibiting BTK, ibrutinib and acalabrutinib also strongly inhibit four other kinases. To ensure that inhibition of BTK, indeed, accounts for the inhibition of NF-kB and the inflammasome and ultimately the observed beneficial effects in sepsis, it would be useful to repeat our study in BTK knockout mice. Interestingly, of the kinases which are strongly inhibited by ibrutinib and acalabrutinib, expression of ErbB4 (rather than its activation) may play a role in the cardiac dysfunction and cognitive impairment associated with sepsis ([@B40]). In contrast, RIP2 kinase is unlikely to play a significant role in sepsis, as the CLP-induced septic peritonitis was similar in RIP2 knockout mice and their wild-type litter mates ([@B41]).

Conclusions {#s5}
===========

There are currently no specific treatments, which reduce the cardiac dysfunction or, indeed, mortality in sepsis. Our data shows for the first time that two commercially available BTK inhibitors, ibrutinib or acalabrutinib, attenuate the CLP-induced cardiac dysfunction through inhibition of the activation of BTK/NF-κB and/or the NLRP3 inflammasome, which in turn reduces the formation of a number of chemokines and cytokines including TNF-α. Notably, no significant qualitative or quantitative differences were found with two, chemically distinct BTK-inhibitors suggesting that the observed beneficial effects of both compounds in experimental sepsis are likely to be a drug class related effect. Thus, BTK inhibitors are FDA-approved drugs that maybe repurposed for the use in sepsis, but also for other diseases associated with either local or systemic inflammation.
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###### 

Systemic inflammation in CLP mice is reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP, blood samples were collected, and the serum concentration of cytokines and chemokines were measured by a multiplex assay (*n* = 8 per group). All data are expressed as mean ± SEM for *n* number of observations. A value of ^\*\*\*\*^*P* \< 0.0001, ^\*\*\*^ *P* \< 0.001, ^\*\*^*P* \< 0.01, ^\*^*P* \< 0.05 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test. A value of ^\$\$\$\$^*P* \< 0.0001, ^\$\$^*P* \< 0.01 was considered to be statistically significant when compared to the sham by one-way ANOVA followed by a Bonferroni\'s *post-hoc* test.
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Click here for additional data file.
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